Cet anticorps anti-ErbB2/Her2 (Pertuzumab Biosimilar) est un anticorps Humanized Monoclonal détectant ErbB2/Her2 (Pertuzumab Biosimilar) dans FACS et in vivo. Adapté pour Humain.
N° du produit ABIN7200658
Aperçu rapide pour Recombinant ErbB2/Her2 (Pertuzumab Biosimilar) anticorps (ABIN7200658)
Antigène
ErbB2/Her2 (Pertuzumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp ErbB2/Her2 (Pertuzumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Fonction
Pertuzumab Biosimilar, Human HER2 Monoclonal Antibody
Specificité
The monoclonal antibody pertuzumab biosimilar specifically binds to the human HER2/ErbB-2/c-neu.
Attributs du produit
Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method
Immunogène
The monoclonal antibody pertuzumab biosimilar was produced in the pertuzumab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
> 3 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Stock
4°C,-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.